Intensive chemotherapy followed by donor PBSC in ANLL, relapsed after allogeneic BMT

P. Bernasconi, E. P. Alessandrino, D. Caldera, M. Bonfichi, M. Boni, D. Troletti, G. Pagnucco, P. Cavigliano, C. Perotti, G. Biaggi, C. Bernasconi

Research output: Contribution to journalArticlepeer-review


We describe a 42-year-old man with ANLL-M4 in relapse after allogeneic BMT, in whom a new CR was obtained by conventional chemotherapy followed by the infusion of his female donor PBSC. At the time of BMT he was in CR. Six months later a full hematological relapse occurred and a three drug 5-day regimen was started. Two days after the end of chemotherapy he received donor PBSC collected by two leukaphereses after mobilization with G-CSF, given subcutaneously at 5 μg/kg/day for 7 days. The mononuclear PBSC were 4.2 x 108/kg; the CD34 positive cells were 8.2 x 106/kg and the CFU-GM were 14 x 104/kg. Two days after PBSC infusion the patient received G-CSF at a dose of 5 μg/kg/day. Hemopoietic recovery occurred promptly on day +13 and Y-FISH revealed 14% of Y-spot positive cells in the marrow. On day +20 hematological and cytogenetic remission was documented. The percentage of recipient cells decreased from day +36 onwards following the occurrence of a grade II GVHD, from which the patient recovered 1 week later with oral cyclosporin A and intravenous high-dose steroids. At present (day +200 from relapse) the patient is still in CR with 3% of Y-spot positive cells.

Original languageEnglish
Pages (from-to)643-645
Number of pages3
JournalBone Marrow Transplantation
Issue number4
Publication statusPublished - 1995


  • Allogeneic BMT
  • Chemotherapy + PBSC
  • Relapsed ANLL

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Intensive chemotherapy followed by donor PBSC in ANLL, relapsed after allogeneic BMT'. Together they form a unique fingerprint.

Cite this